News
In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (NASDAQ: RXRX) is slimming ...
Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback